Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMET PRO: Surgery vs Medical Treatment in Microprolactinomas
2023-000082-13Phase 3Active
- Sponsor
- Azienda USL di Bologna
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabergoline in prolactinoma (2 arms), sponsored by Azienda USL di Bologna. Primary endpoint: Biochemical remission at 6 and 12 months. Started Feb 2023; status: active.
02
Drugs
cabergoline
03
Conditions
prolactinoma
Beyond the preview
Go deeper on 2023-000082-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000082-13.